The first overall survival data from the Phase 3 CheckMate -067 clinical trial
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE:BMY) today announced the first overall survival (OS) data from the Phase 3 CheckMate -067 clinical trial. With a minimum follow-up of 28 months, the median OS had not yet been reached in either of the two Opdivo treatment groups and was 20 months for the Yervoy monotherapy group (95% CI: 17.1-24.6). Opdivo in combination with Yervoy and as a monotherapy reduced the risk of death 45% [hazard ratio (HR) 0.55; 95% CI: 0.42-0.72; P<0.0001] and 37% (HR 0.63; 95% CI: 0.48-0.81; P<0.0001), respectively, compared with Yervoy alone.
Tagrisso (osimertinib) receives US FDA full approval
- Details
- Category: AstraZeneca
AstraZeneca today announced that the US Food and Drug Administration (FDA) has granted full approval for Tagrisso (osimertinib) 80mg once-daily tablets, for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test, whose disease has progressed on or after an EGFR tyrosine kinase inhibitor (TKI) therapy.
Merck advances R&D strategy through unique development model with Avillion for Anti IL-17 A/F Nanobody
- Details
- Category: Merck Group
Merck, a leading science and technology company, today announced a development agreement with Avillion, a UK-based company focused on increasing R&D output through innovative models, for anti IL-17 A/F Nanobody®. Merck's Anti IL-17 A/F Nanobody® is an investigational therapy which has completed Phase I development, and is expected to begin Phase II in plaque psoriasis in 2017.
Daiichi Sankyo announces collaborative research on drugs for neglected tropical diseases
- Details
- Category: Daiichi Sankyo
Daiichi Sankyo Company, Limited (Daiichi Sankyo), announced that it has entered into a new joint research agreement with the Drugs for Neglected Diseases initiative (DNDi) with regard to a new research program, the Hit-to-Lead Project, with the aim of developing drug treatments for two neglected tropical diseases (NTDs), leishmaniasis and Chagas disease.
FDA approves Roche's OCREVUS™ (ocrelizumab) for relapsing and primary progressive forms of multiple sclerosis
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) approved OCREVUS™ (ocrelizumab) as the first and only medicine for both relapsing and primary progressive forms of multiple sclerosis. The majority of people with MS have a relapsing form or primary progressive MS at diagnosis.
Parker Institute for Cancer Immunotherapy, Bristol-Myers Squibb and the Cancer Research Institute announce collaboration to accelerate immuno-oncology research
- Details
- Category: Bristol-Myers Squibb
The Parker Institute for Cancer Immunotherapy, Bristol-Myers Squibb Company (NYSE: BMY) and the Cancer Research Institute (CRI) today announced a multi-year clinical research collaboration to coordinate and rapidly initiate clinical Immuno-Oncology (I-O) studies across the Parker Institute and CRI networks. Bristol-Myers Squibb will work closely with leading Parker Institute and CRI scientists and researchers,
Astrazeneca to share its robust early science in oncology with the medical community at AACR 2017
- Details
- Category: AstraZeneca
AstraZeneca, along with its global biologics research and development arm, MedImmune, will present the strength and depth of its translational science, which is expected to deliver the Company's next wave of innovative oncology medicines, at the American Association for Cancer Research (AACR) Annual Meeting in Washington DC, US, 1-5 April 2017.
More Pharma News ...
- XELJANZ® (tofacitinib citrate) receives marketing authorisation in the European Union for the treatment of moderate to severe active rheumatoid arthritis
- Bayer's Rivaroxaban demonstrated superior protection against recurrent venous thromboembolism compared with Aspirin in EINSTEIN CHOICE study
- Novartis' Cosentyx is first and only IL-17A inhibitor to potentially modify the course of psoriasis
- Merck Accelerator hits new peak of applications
- New analysis shows Novartis Entresto improves glycemic control in reduced ejection fraction heart failure patients with diabetes
- Landmark outcomes study shows that Repatha® (Evolocumab) decreases LDL-C to unprecedented low levels and reduces risk of cardiovascular events
- AstraZeneca and Circassia enter strategic collaboration in respiratory disease